Meta

Trianni, Inc. Announces License Agreement with Zymeworks Inc. for use of the Trianni Mouse®

Trianni /

September 10, 2019

San Francisco, CA, Sept. 10, 2019 – Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement with Zymeworks
Inc. (“ZYMEWORKS”) for the use of the Trianni Mouse®, a transgenic mouse
R&D platform for the discovery of fully-human monoclonal antibodies, to support ZYMEWORKS’
therapeutic discovery programs.

“TRIANNI is pleased that Zymeworks has chosen the Trianni
Mouse for the development of novel, fully human, antibody-based therapeutics” said Matthias Wabl, PhD, Chairman,
President and CEO of TRIANNI. “We are
confident that combining Zymeworks’ unique, best-in-class platforms with the
power of the Trianni Mouse will lead to the development of transformative
medicines for the treatment of underserved patient populations.”